Trial Registrations Reflect Improved Funding
The impact of the strong funding environment for emerging bio/pharma companies is being reflected in new clinical trial starts. An analysis of new clinical trial registrations in the clinicaltrials.gov database indicates that Phase I and II trial starts for which an emerging bio/pharma company is the sponsor or principal collaborator were up 65% in the first half of 2012 versus the first half of 2016 (Figure 1).
The jump in trial registrations is closely correlated to the improved funding environment that emerging bio/pharma companies have enjoyed in recent years. External funding for emerging biopharma companies in 2015, i.e., the funding year immediately preceding the 2016 trial registrations, was more than three times as high as the funding those companies received in 2011, the year before the 2012 registrations. Clearly the emerging bio/pharma companies are using that money to advance their pipelines.
Interestingly, our analysis indicates that Phase I and II trial registrations in which global bio/pharma companies were the sponsors or principal collaborators were 34% lower in 2016 than in 2015, despite increased R&D spending at the global bio/pharma companies, as shown in Figure 1.
This article is reprinted from the October issue of Bio/pharmaceutical Outsourcing Report. The full article addresses the decline in clinical trial registrations and its impact on CDMOs. To learn more, click here.